ADVISORY/Experts Available To Discuss Drug Treatment for Mild Cognitive Impairment.Business Editors ADVISORY... --(BUSINESS WIRE) TOPIC: Many experts suggest developing treatment for early memory impairment may help stave off Alzheimer's disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. , according to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. an article by BusinessWeek Online. Cortex Pharmaceuticals Inc.'s memory drug is now in Phase 2 clinical trials phase 2 clinical trial Phase 2 study. See Phase study. for people who suffer from mild cognitive impairment mild cognitive impairment (MCI), n memory loss generally associated with aging; does not affect normal independent functioning of an individual. (MCI (1) (Media Control Interface) A high-level programming interface from Microsoft and IBM for controlling multimedia devices. It provides commands and functions to open, play and close the device. (2) (Microwave Communications Inc. ), a condition in which a person experiences frequent short-term memory short-term memory n. Abbr. STM The phase of the memory process in which stimuli that have been recognized and registered are stored briefly. lapses. According to the article, 15% of people diagnosed with MCI develop Alzheimer's each year. EXPERTS: ExpertSource can offer several highly qualified experts to comment on this story: Roger G. Stoll, Ph.D. is the chairman, president, and chief executive officer of Cortex Pharmaceuticals. Dr. Stoll has over 30 years of experience in the pharmaceutical, medical devices, and diagnostic industries. He can share his insight on the new drugs to treat memory loss (mild cognitive impairment & Alzheimer's). Most recently, he was the Executive Vice President of Fresenius Medical Care Fresenius Medical Care is a German company specializing in the production of medical supplies, primarily to facilitate or aid renal dialysis. It is 37%-owned by the health care company Fresenius SE. - N. America, in charge of both the dialysis products and laboratory services. Dr. Stoll oversaw the company's manufacturing, sales, service, research and development, and business development functions, and was responsible for combined sales of approximately $900 million as well as more than 3,000 employees. In addition to the Cortex board, Dr. Stoll currently serves as a member of the boards of directors of Agensys, Inc., Questcor Pharmaceuticals, Inc., and LifePoint, Inc. PR Contact: Janet Vasquez 212-825-3210 theproteam@aol.com Dr. Rodney Pearlman, president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Saegis Pharmaceuticals, Inc., can discuss the development of new drugs to protect and enhance memory and cognition. He received his Ph.D. in Pharmaceutical Chemistry focused on delivery of drugs to the brain, studying with the late Professor Takeru Higuchi and Professor Nicholas Bodor, pioneers in the field of Drug Delivery. Dr. Pearlman worked for Eli Lilly Eli Lilly can refer to:
Professor Barry Oken, of Oregon Health Sciences University, is neurologist and research clinical neuroscientist who is an expert on cognitive neuroscience and Alzheimer's disease. 503-494-8873 ExpertSource cannot guarantee the immediate availability of these experts or their familiarity with this specific issue. ExpertSource provides academic and industry experts to the media at no charge. Journalists are encouraged to submit queries to ExpertSource when seeking experts on specific subjects. An online registration form is available at http://www.businesswire.com/. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion